Abstract
BackgroundPembrolizumab (pembro) ± chemotherapy is a standard-of-care first-line (1L) treatment option for recurrent/metastatic (R/M) PD-L1+ head and neck squamous cell carcinoma (HNSCC). Pembro monotherapy is often used in patients with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
